HealthJOIN4ATMP
Helping New Gene and Cell Therapies Reach Patients Faster in Europe
At a Glance
- Accelerating and de-risking European Advanced Therapy Medicinal Product (ATMP) development
- Ensuring wide-spread access of ATMPs through mapping obstacles, auditing real-world-based solutions and the definition of new paths forward
Bridging Regulatory Gaps to Unlock the Full Potential of ATMP Innovation in the EU
Current legal and regulatory frameworks for drug development in the EU have been designed for standard drug production with large patient target groups. Meanwhile, several regulatory, clinical, economic and ethical issues remain unsolved and account for missed opportunities to develop ground-breaking technologies and ATMP success. This is where Join4ATMP aims to make its mark.
Addressing the Challenges in the Clinical Translation of Alternative Therapies for Multiple Diseases
In pursuit of accelerating ATMP development in Europe and fostering their access into clinical practice in Europe, JOIN4ATMP:
- maps existing and potential future barriers for ATMP development in the market and clinical setting
- defines a set of recommendations based on real-world cases to overcome these hurdles
- proposes a sustainable model for ATMPs to coordinate activities in Europe beyond the project duration
- increases the awareness of patients and the general public of the importance of ATMPs
